Ingelheim/Germany, 16 September 2010 - Boehringer Ingelheim announced today that the European Commission has approved an update to the Summary of Product Characteristics (SmPC) for VIRAMUNE® (nevirapine) in the treatment of patients with HIV.
The label change means that HIV -1 patients with an undetectable viral load can switch to treatment with Viramune® regardless of their CD4 count.
A large body of clinical evidence demonstrates that the risk of hypersensitivity and/or hepatotoxicity in treatment-experienced HIV patients switching to Viramune® is not increased among those with an undetectable viral load (< 50 copies/ml) and CD4 counts above the gender specific CD4-thresholds identified for treatment-naïve patients 1-4.
“This is good news for all HIV patients looking to change their HIV treatments to a Viramune®-based regimen because of drug resistance, side effects or drug interactions,” said Professor Jürgen Rockstroh, University Bonn. “Prescribing physicians will now no longer have to apply the CD4 count threshold when switching patients to a lipid-friendly regimen containing Viramune®.”
The decision followed a positive recommendation by the Committee for Medical Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) who reviewed the clinical evidence and approved the new wording in the Viramune® Summary of Product Characteristics.
This new label change is based on data from more than 12,000 patients, including a meta-analysis of randomised prospective studies, a retrospective analysis of a single centre HIV cohort and observational studies (EuroSIDA cohort, ATHENA cohort and multi-cohort studies). 1-4 These studies found that the risk of hypersensitivity and/or hepatotoxicity in patients with an undetectable viral load switching to Viramune® is not increased in patients with higher CD4 counts (i.e. above the gender specific CD4-thresholds: women more than 250 cells/mm³, men more than 400 cells/mm³).
Notes to Editors
In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.
Please be advised